Pharma Major Lupin Limited on Tuesday said that its US subsidiary, Lupin Pharmaceuticals, has launched its Metformin HCl ER Tablets, 500 mg and 1000 mg to market a generic equivalent of Santarus Inc.’s Glumetza HCl ER Tablets, 500 mg and 1000 mg.
“Lupin’s Metformin HCl ER Tablets, 500 mg and 1000 mg are the AB-rated generic equivalent of Santarus Inc.’s Glumetza HCl ER Tablets, 500 mg and 1000 mg strengths. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus,” the drug maker said in a filing to Bombay Stock Exchange.
Lupin is eligible for 180 days of generic drug exclusivity for its Metformin HCl ER Tablets, 500 mg and 1000 mg, it said in the filing.
Glumetza HCI ER Tablets had US sales of USD 450.4 million (IMS MAT September 2015).
Following the announcement, shares of company were trading at Rs 1723.95 apiece, up 1.33 per cent, from previous close on BSE at 14:55 hours.